ESMO: Erbitux No Help in Esophageal Ca (CME/CE)
(MedPage Today) -- Survival in esophageal cancer did not improve with the addition of cetuximab (Erbitux) to conventional chemoradiation, results of a randomized trial showed. The study was among several notable reports from the European Society for Medical Oncology World Congress on Gastrointestinal Cancer.
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
More News: Cancer | Cancer & Oncology | Erbitux | Esophagus Cancer | Gastroenterology | Politics | Primary Care | Study